2021 Revenues ($USD) : $5,915,354,331
2021 Revenues (foreign currencies) : CHF5,409,000,000
2021 R&D spend : na
2021 Number of Employees : 16,218
Fiscal Year End : 12/31/2021
Leader : CEO Pierre-Alain Ruffieux

The Swiss contract development and manufacturing company saw 20% growth in 2021, adding approximately 170 new customers. In 2021, it made several investments to drive further growth, including ramping up its capsule manufacturing capability. It also brought a microbial service offering online in Switzerland in addition to a validated clinical drug substance facility in China. —BB